[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,867,702
  • Shares Outstanding, K 51,460
  • Annual Sales, $ 638,500 K
  • Annual Income, $ -183,170 K
  • EBIT $ -167 M
  • EBITDA $ -156 M
  • 60-Month Beta 0.59
  • Price/Sales 18.27
  • Price/Cash Flow N/A
  • Price/Book 213.68

Options Overview Details

View History
  • Implied Volatility 34.46% (+0.07%)
  • Historical Volatility 48.17%
  • IV Percentile 12%
  • IV Rank 10.02%
  • IV High 82.40% on 04/29/26
  • IV Low 29.12% on 01/22/26
  • Expected Move (DTE 28) 15.39 (6.59%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 2,600
  • Volume Avg (30-Day) 2,291
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 27,928
  • Open Int (30-Day) 31,144
  • Expected Range 218.25 to 249.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.81
  • Number of Estimates 8
  • High Estimate $0.15
  • Low Estimate $-1.60
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) +11.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
180.00 +29.80%
on 04/29/26
235.91 -0.96%
on 05/13/26
+50.67 (+27.69%)
since 04/21/26
3-Month
152.28 +53.43%
on 03/24/26
235.91 -0.96%
on 05/13/26
+49.92 (+27.17%)
since 02/20/26
52-Week
96.09 +143.15%
on 08/04/25
235.91 -0.96%
on 05/13/26
+127.88 (+120.92%)
since 05/21/25

Most Recent Stories

More News
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder,...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 233.64 (+1.31%)
Axsome: Q1 Earnings Snapshot

Axsome: Q1 Earnings Snapshot

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY ® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth ...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Reports Its First Quarter Since Doubling Down on Sales Infrastructure

Barchart Research What to Expect from AXSM Earnings AXSM Generated May 1, 2026 Current Price $206.53 EPS Estimate $$-0.85 Consensus Rating Strong Buy Average Move 3.41% Axsome Therapeutics Reports Its...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Reports Its First Quarter Since Doubling Down on Sales Infrastructure

Barchart Research What to Expect from AXSM Earnings AXSM Generated May 1, 2026 Current Price $206.53 EPS Estimate $$-0.85 Consensus Rating Strong Buy Average Move 3.41% Axsome Therapeutics Reports Its...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Reports Its First Quarter Since Doubling Down on Sales Infrastructure

Barchart Research What to Expect from AXSM Earnings AXSM Generated May 1, 2026 Current Price $206.53 EPS Estimate $$-0.85 Consensus Rating Strong Buy Average Move 3.41% Axsome Therapeutics Reports Its...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host...

AXSM : 233.64 (+1.31%)
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease  The safety and tolerability profile...

AXSM : 233.64 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 248.41
2nd Resistance Point 241.60
1st Resistance Point 237.62
Last Price 233.64
1st Support Level 226.83
2nd Support Level 220.02
3rd Support Level 216.04

See More

52-Week High 235.91
Last Price 233.64
Fibonacci 61.8% 182.50
Fibonacci 50% 166.00
Fibonacci 38.2% 149.50
52-Week Low 96.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.